Overview
Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its pharmaceutical unit specializes in rare diseases, multiple sclerosis (MS), oncology, immunology, diabetes, and cardiovascular illness; the big sellers are Aubagio (MS), Lantus (diabetes), Lovenox (thrombosis), and Plavix (atherothrombosis). Sanofi's vaccines business, Sanofi Pasteur,
...
Read More manufactures vaccines for flu, meningitis, and pneumonia and its consumer healthcare business makes cough and cold, pain, and digestive remedies. With business operations in approximately 90 countries and its products are available in more than 170 countries; the US is Sanofi's biggest market.
Read Less
Read More manufactures vaccines for flu, meningitis, and pneumonia and its consumer healthcare business makes cough and cold, pain, and digestive remedies. With business operations in approximately 90 countries and its products are available in more than 170 countries; the US is Sanofi's biggest market.
Read Less
Frédéric OUDÉA
See more contacts
Management of Companies and Enterprises
,
Holding companies, nec
?
Actual
$46.83 billion
Actual
6.41%
2.96%
$132,798
DEC
?
?
Euronext Paris:SAN
Contacts
Get in Touch with 17 Principals*
-
Frédéric OUDÉAChairman of the Board
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$46.83 billion
USD
Actual
1 USD = 0.9456 EUR
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $9,603 | $10,848 | $11,131 |
| Net Investing Cash | -$4,660 | -$6,557 | -$2,194 |
| Net Financing Cash | -$6,094 | -$8,515 | -$6,156 |
| Net Change in Cash | -$1,328 | -$4,224 | $2,781 |
| Cash at Beginning of Period | $9,211 | $13,468 | $10,679 |
| Cash at End of Period | $7,869 | $9,211 | $13,468 |
| Capital Expenditure | -$3,379 | -$3,073 | -$2,224 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $7,869 | $9,211 | $13,468 |
| Accounts Receivable | $8,118 | $8,918 | $8,908 |
| Inventories | $9,973 | $10,222 | $9,475 |
| Other Current Assets | $19,076 | $4,083 | $4,219 |
| Asset Summary | |||
| Total Current Assets | $45,037 | $32,434 | $36,072 |
| Tangible Fixed Assets | $12,268 | $12,493 | $12,356 |
| Intangible Assets | $23,930 | $25,718 | $22,884 |
| Total Assets | $132,798 | $126,464 | $126,722 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $7,985 | $7,749 | $7,205 |
| Short-Term Debt | $4,451 | $2,163 | $4,414 |
| Other Current Liabilities | $18,403 | $15,687 | $13,734 |
| Liability Summary | |||
| Total Current Liabilities | $30,839 | $25,599 | $25,353 |
| Long-Term Debt | $12,469 | $15,172 | $15,711 |
| Other Long-Term Liabilities | $3,070 | $3,004 | $1,262 |
| Total Liabilities | $58,101 | $55,108 | $54,536 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $2,671 | $2,675 | $2,667 |
| Retained Earnings | $ | $ | $ |
| Equity Summary | |||
| Total Equity | $81,964 | $78,298 | $79,085 |
| Shares Outstanding | 1,253,591,640 | 1,251,349,581 | 1,260,835,732 |